vs
ANI PHARMACEUTICALS INC（ANIP）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $188.3M、BRC Group Holdings, Inc.の約1.3倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs 11.1%、差は36.8%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -21.9%）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -15.4%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ANIP vs RILY — 直接比較
売上が大きい
ANIP
1.3倍大きい
$188.3M
売上成長率が高い
ANIP
+51.5%の差
-21.9%
純利益率が高い
RILY
純利益率が36.8%高い
11.1%
2年売上CAGRが高い
ANIP
2年複合成長率
-15.4%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $188.3M |
| 純利益 | $27.5M | $90.3M |
| 粗利率 | — | 79.5% |
| 営業利益率 | 14.1% | 32.3% |
| 純利益率 | 11.1% | 47.9% |
| 売上前年比 | 29.6% | -21.9% |
| 純利益前年比 | 367.5% | 1710.8% |
| EPS（希薄化後） | $1.14 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ANIPRILY
| Q4 25 | $247.1M | $188.3M | ||
| Q3 25 | $227.8M | $215.3M | ||
| Q2 25 | $211.4M | $188.2M | ||
| Q1 25 | $197.1M | $197.2M | ||
| Q4 24 | $190.6M | $241.0M | ||
| Q3 24 | $148.3M | $225.5M | ||
| Q2 24 | $138.0M | $256.0M | ||
| Q1 24 | $137.4M | $263.4M |
純利益ANIPRILY
| Q4 25 | $27.5M | $90.3M | ||
| Q3 25 | $26.6M | $91.1M | ||
| Q2 25 | $8.5M | $139.5M | ||
| Q1 25 | $15.7M | $-10.0M | ||
| Q4 24 | $-10.3M | $-5.6M | ||
| Q3 24 | $-24.2M | $-284.4M | ||
| Q2 24 | $-2.3M | $-433.6M | ||
| Q1 24 | $18.2M | $-49.2M |
粗利率ANIPRILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
営業利益率ANIPRILY
| Q4 25 | 14.1% | 32.3% | ||
| Q3 25 | 15.9% | 30.4% | ||
| Q2 25 | 6.6% | 5.7% | ||
| Q1 25 | 13.3% | -31.2% | ||
| Q4 24 | -2.3% | -69.2% | ||
| Q3 24 | -13.8% | -36.4% | ||
| Q2 24 | 3.7% | -90.8% | ||
| Q1 24 | 14.8% | -6.1% |
純利益率ANIPRILY
| Q4 25 | 11.1% | 47.9% | ||
| Q3 25 | 11.7% | 42.3% | ||
| Q2 25 | 4.0% | 74.1% | ||
| Q1 25 | 8.0% | -5.1% | ||
| Q4 24 | -5.4% | -2.3% | ||
| Q3 24 | -16.3% | -126.1% | ||
| Q2 24 | -1.7% | -169.4% | ||
| Q1 24 | 13.2% | -18.7% |
EPS（希薄化後）ANIPRILY
| Q4 25 | $1.14 | $2.78 | ||
| Q3 25 | $1.13 | $2.91 | ||
| Q2 25 | $0.36 | $4.50 | ||
| Q1 25 | $0.69 | $-0.39 | ||
| Q4 24 | $-0.45 | $-0.01 | ||
| Q3 24 | $-1.27 | $-9.39 | ||
| Q2 24 | $-0.14 | $-14.35 | ||
| Q1 24 | $0.82 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $226.6M |
| 総負債低いほど良い | — | $1.4B |
| 株主資本純資産 | $540.7M | $-171.5M |
| 総資産 | $1.4B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資ANIPRILY
| Q4 25 | $285.6M | $226.6M | ||
| Q3 25 | $262.6M | $184.2M | ||
| Q2 25 | $217.8M | $267.4M | ||
| Q1 25 | $149.8M | $138.3M | ||
| Q4 24 | $144.9M | $146.9M | ||
| Q3 24 | $145.0M | $159.2M | ||
| Q2 24 | $240.1M | $236.9M | ||
| Q1 24 | $228.6M | $190.7M |
総負債ANIPRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
株主資本ANIPRILY
| Q4 25 | $540.7M | $-171.5M | ||
| Q3 25 | $505.8M | $-260.5M | ||
| Q2 25 | $436.8M | $-351.7M | ||
| Q1 25 | $418.6M | $-496.8M | ||
| Q4 24 | $403.7M | $-488.2M | ||
| Q3 24 | $405.9M | $-497.6M | ||
| Q2 24 | $455.8M | $-218.3M | ||
| Q1 24 | $452.0M | $228.4M |
総資産ANIPRILY
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $2.2B | ||
| Q2 24 | $920.8M | $3.2B | ||
| Q1 24 | $914.5M | $5.0B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | — |
| FCFマージンFCF / 売上 | 11.8% | — |
| 設備投資強度設備投資 / 売上 | 0.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローANIPRILY
| Q4 25 | $30.4M | $26.2M | ||
| Q3 25 | $44.1M | $-60.6M | ||
| Q2 25 | $75.8M | $-25.6M | ||
| Q1 25 | $35.0M | $184.0K | ||
| Q4 24 | $15.9M | $-2.7M | ||
| Q3 24 | $12.5M | $19.5M | ||
| Q2 24 | $17.4M | $111.5M | ||
| Q1 24 | $18.3M | $135.4M |
フリーキャッシュフローANIPRILY
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
FCFマージンANIPRILY
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
設備投資強度ANIPRILY
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
キャッシュ転換率ANIPRILY
| Q4 25 | 1.10× | 0.29× | ||
| Q3 25 | 1.66× | -0.66× | ||
| Q2 25 | 8.87× | -0.18× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
